Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)

被引：1

作者：

Franklin, Anna ^{[1
]}

Zecca, Marco ^{[2
]}

Fagioli, Franca ^{[3
]}

Luisi, Flavio Augusto ^{[4
]}

Song, Gregory ^{[5
]}

Suri, Ajit ^{[5
]}

Leonard, E. Jane ^{[5
]}

Locatelli, Franco ^{[6
]}

机构：

[1] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO USA

[2] Fdn IRCCS Policlin San Matteo, Pediat Hematol Oncol, Pavia, Italy

[3] Univ Turin, Childrens Hosp Regina Margherita, Turin, Italy

[4] Grp Apoio Ao Adolescente & Crianca Com Canc, Sao Paulo, Brazil

[5] Millennium Pharmaceut Inc, Cambridge, MA USA

[6] IRCCS Osped Pediat Bambino Gesu, Dept Pediat Hematol Oncol & Cell & Gene Therapy, Rome, Italy

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112488

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1644

引用

页数：2

共 50 条

[1] Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL).
Keating Franklin, Anna Rachel
Luisi, Flavio
Pianovski, Mara
Salvino, Marco Aurelio
Fagioli, Franca
Epelman, Sidnei
Lima, Luciana
Norris, Robin Elizabeth
Odone-Filho, Vicente
Zecca, Marco
Favre, Claudio
Kobayashi, Ryoji
Koga, Yuhki
Sidi, Yulia
Zhou, Xiaofei
Bai, Xiang
Campana, Frank
Leonard, E. Jane
Locatelli, Franco
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] PHASE 1/2 STUDY: FRONTLINE BRENTUXIMAB VEDOTIN plus AVD IN PEDIATRIC PTS WITH ADVANCED HODGKIN LYMPHOMA
Franklin, Anna
Zecca, Marco
Fagioli, Franca
Luisi, Flavio Augusto
Song, Gregory
Suri, Ajit
Leonard, E. Jane
Locatelli, Franco
PEDIATRIC BLOOD & CANCER, 2019, 66
[3] Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study
Engert, A.
Domingo Domenech, E.
Rueda, A.
Armand, P.
Trneny, M.
Feldman, T.
Ansell, S.
Provencio, M.
Jaeger, U.
Cohen, J. B.
Savage, K. J.
Willenbacher, W.
Sacchi, M.
Sumbul, A.
Ramchandren, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 273 - 273
[4] PHASE 1/2 STUDY DESIGN: FRONTLINE BRENTUXIMAB VEDOTIN plus AVD IN PEDIATRIC ADVANCED HODGKIN LYMPHOMA
Franklin, Anna
Zecca, Marco
Luisi, Flavio Augusto
Song, Gregory
Suri, Ajit
Leonard, E. Jane
Locatelli, Franco
PEDIATRIC BLOOD & CANCER, 2019, 66
[5] Results from an Open-Label, Phase 1/2 Study of Frontline Brentuximab Vedotin Plus Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients with Advanced Stage Hodgkin Lymphoma
Franklin, A.
Luisi, F.
Pianovski, M.
Salvino, M.
Fagioli, F.
Epelman, S.
De Abreu Lima, L. B.
Norris, R.
Filho, V. O.
Zecca, M.
Favre, C.
Kobayashi, R.
Koga, Y.
Sidi, Y.
Campana, F.
Leonard, E. J.
Locatelli, F.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S78 - S79
[6] Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
Younes, Anas
Radford, John
Ansell, Stephen Maxted
Gallamini, Andrea
Kim, Wom Seog
Feldman, Tatyana A.
Hamadani, Mehdi
Chung, Jeanenne
Wang, Jingyuan
Huebner, Dirk
Connors, Joseph M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study
Ansell, Stephen Maxted
Younes, Anas
Connors, Joseph M.
Gallamini, Andrea
Kim, Won Seog
Friedberg, Jonathan W.
Feldman, Tatyana A.
Collins, Graham
Bartlett, Nancy
Wang, Jingyuan
Brady, Kelly
Sachs, Jessica
Huebner, Dirk
Hunder, Naomi N. H.
Radford, John
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Herrera, Alex F.
Li, Hongli
Castellino, Sharon M.
Rutherford, Sarah C.
Davison, Kelly
Evans, Andrew G.
Punnett, Angela
Constine, Louis S.
Hodgson, David C.
Parsons, Susan K.
Prica, Anca
Kostakoglu, Lale
Shipp, Margaret A.
Laubach, Cara
Leblanc, Michael L.
Crump, Michael
Kahl, Brad S.
Leonard, John P.
Kelly, Kara M.
Smith, Sonali M.
Friedberg, Jonathan W.
BLOOD, 2020, 136
[9] Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study
Lee, Hun Ju
Flinn, Ian W.
Melear, Jason
Ramchandren, Rod
Friedman, Judah
Burke, John M.
Linhares, Yuliya
Gonzales, Paul Alan
Raval, Mihir
Chintapatla, Rangaswamy
Feldman, Tatyana
Yimer, Habte A.
Islas-Ohlmayer, Miguel
Dean, Asad
Rana, Vishal
Gandhi, Mitul
Renshaw, John Scott
Ho, Linda
Fanale, Michelle A.
Guo, Wenchuan
Yasenchak, Chris
BLOOD, 2023, 142
[10] Brentuximab Vedotin Plus AVD for Non-Bulky Limited Stage Classical Hodgkin Lymphoma: A Phase 2 Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 17 - 18

← 1 2 3 4 5 →